
Vertex Pharmaceuticals Investor Relations Material
Latest events

Q1 2025
Vertex Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Vertex Pharmaceuticals Inc
Access all reports
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Its products include KALYDECO (ivacaftor), ORKAMBI (lumacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), VX-445, and VX-659, as well as other product candidates at various stages of research, development, and commercialization. The company has collaboration agreements with CRISPR Therapeutics AG; Moderna, Inc.; CRISPR Therapeutics AG; Editas Medicine, Inc.; Frontline BioVentures; Merck & Co., Inc.; Cystic Fibrosis Foundation Therapeutics, Incorporated; Bristol-Myers Squibb Company; Altimmune, Inc.; and Tesaro, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key slides for Vertex Pharmaceuticals Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Vertex Pharmaceuticals Inc


Q1 2025
Vertex Pharmaceuticals Inc
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
VRTX
Country
🇺🇸 United States